{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:40:05Z","timestamp":1759974005252,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.medmal.2009.08.014","type":"journal-article","created":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T04:22:28Z","timestamp":1256790148000},"page":"871-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Le dorip\u00e9n\u00e8me\u00a0: quelle place pour un nouveau carbap\u00e9n\u00e8me\u00a0?"],"prefix":"10.1016","volume":"39","author":[{"given":"B.-P.","family":"Guery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2009.08.014_bib1","unstructured":"Enqu\u00eate nationale de pr\u00e9valence des infections nosocomiales. www.invs.sante.fr 2006 (site consult\u00e9 en janvier 2009)."},{"issue":"Suppl. 1","key":"10.1016\/j.medmal.2009.08.014_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1469-0691.2007.01850.x","article-title":"Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe","volume":"14","author":"Canton","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2009.08.014_bib3","first-page":"13","article-title":"Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe","author":"Coque","year":"2008","journal-title":"Euro Surveill"},{"key":"10.1016\/j.medmal.2009.08.014_bib4","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1128\/JCM.01008-08","article-title":"High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients","volume":"46","author":"Valverde","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.medmal.2009.08.014_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2009.08.014_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/dkh298","article-title":"Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations","volume":"54","author":"Jones","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bcp.2005.12.003","article-title":"Redefining penems","volume":"71","author":"Dalhoff","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.medmal.2009.08.014_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2009.08.014_bib9","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1128\/AAC.49.10.4413-4417.2005","article-title":"In vitro activities of doripenem and comparator agents against 364\u00a0anaerobic clinical isolates","volume":"49","author":"Wexler","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dki134","article-title":"Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control","volume":"55","author":"Brown","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/AAC.48.4.1384-1396.2004","article-title":"In vitro antimicrobial activity of doripenem, a new carbapenem","volume":"48","author":"Ge","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.08.014_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1128\/AAC.50.2.819-821.2006","article-title":"In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients","volume":"50","author":"Traczewski","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib14","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1128\/AAC.49.6.2510-2511.2005","article-title":"In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis","volume":"49","author":"Chen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib15","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.48.8.3086-3092.2004","article-title":"Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib17","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","article-title":"Activities of doripenem (S-4661) against drug-resistant clinical pathogens","volume":"48","author":"Jones","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10156-005-0402-2","article-title":"Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan","volume":"11","author":"Kobayashi","year":"2005","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib19","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15\u00a0antimicrobial agents against 110\u00a0toxigenic clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/AAC.00910-07","article-title":"Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis","volume":"52","author":"Credito","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jac\/43.2.309","article-title":"Continuous infusion ceftazidime in intensive care: a randomized controlled trial","volume":"43","author":"Lipman","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1592\/phco.21.6.549.34539","article-title":"Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia","volume":"21","author":"McNabb","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medmal.2009.08.014_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","article-title":"Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia","volume":"17","author":"Nicolau","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.08.014_bib24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.08.014_bib25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1592\/phco.23.8.988.32878","article-title":"Pharmacokinetics of meropenem 0.5 and 2g every 8hours as a 3-hour infusion","volume":"23","author":"Dandekar","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medmal.2009.08.014_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/AAC.49.1.461-463.2005","article-title":"Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation","volume":"49","author":"Lomaestro","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1345\/aph.1G467","article-title":"Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli","volume":"40","author":"Lorente","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.medmal.2009.08.014_bib28","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.clinthera.2008.11.013","article-title":"Stability of doripenem in vitro in representative infusion solutions and infusion bags","volume":"30","author":"Psathas","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2009.08.014_bib29","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.49.9.3944-3947.2005","article-title":"Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase\u00a02 and 3 dosing strategies for doripenem","volume":"49","author":"Bhavnani","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medmal.2009.08.014_bib31","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study","volume":"24","author":"Rea-Neto","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.medmal.2009.08.014_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/109629602761624171","article-title":"The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary","volume":"3","author":"Mazuski","year":"2002","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.medmal.2009.08.014_bib33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/378702","article-title":"Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections","volume":"37","author":"Solomkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.08.014_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchromb.2007.03.004","article-title":"Development of an HPLC method for the determination of doripenem in human and mouse serum","volume":"853","author":"Sutherland","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.medmal.2009.08.014_bib35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dkm371","article-title":"Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients","volume":"60","author":"Ikawa","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jchromb.2008.03.001","article-title":"Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection","volume":"867","author":"Ikeda","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.medmal.2009.08.014_bib37","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2009.08.014_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1179\/joc.2002.14.2.155","article-title":"In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections","volume":"14","author":"Nomura","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib39","first-page":"14","article-title":"Cefazolin: a valid model of experimental epilepsy?","volume":"5","author":"Nistico","year":"1980","journal-title":"Monogr Neural Sci"},{"key":"10.1016\/j.medmal.2009.08.014_bib40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tox.2006.02.004","article-title":"Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics","volume":"222","author":"Horiuchi","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.medmal.2009.08.014_bib41","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.clinthera.2008.04.001","article-title":"Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia","volume":"30","author":"Merchant","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2009.08.014_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00134-001-1172-7","article-title":"Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study","volume":"28","author":"Moine","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medmal.2009.08.014_bib43","doi-asserted-by":"crossref","unstructured":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388\u2013416.","DOI":"10.1164\/rccm.200405-644ST"},{"key":"10.1016\/j.medmal.2009.08.014_bib44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/clinids\/23.3.538","article-title":"Mortality due to ventilated-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush","volume":"23","author":"Fagon","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.08.014_bib45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/archsurg.1996.01430140070019","article-title":"Prognosis and treatment of peritonitis. Do we need new scoring systems?","volume":"131","author":"Koperna","year":"1996","journal-title":"Arch Surg"},{"key":"10.1016\/j.medmal.2009.08.014_bib46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/clinids\/23.3.486","article-title":"Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy","volume":"23","author":"Montravers","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.08.014_bib47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.8.4.557","article-title":"beta-Lactamases in laboratory and clinical resistance","volume":"8","author":"Livermore","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.medmal.2009.08.014_bib48","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.39.9.1948","article-title":"Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa","volume":"39","author":"Li","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib49","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1128\/AAC.44.9.2242-2246.2000","article-title":"Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa","volume":"44","author":"Masuda","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.08.014_bib50","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X09002339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X09002339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:06:17Z","timestamp":1759971977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X09002339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0399077X09002339"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2009.08.014","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le dorip\u00e9n\u00e8me\u00a0: quelle place pour un nouveau carbap\u00e9n\u00e8me\u00a0?","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2009.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}